Showing results (11-20 of 56) with videos related to
Sort By:
Pageof 6
Cell Chemical Biology|June 24, 2023
Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimizationMartin P Schwalm, Andreas Krämer, Anja Dölle, et al.Journal of the American Chemical Society|July 5, 2022
TF-DUBTACs Stabilize Tumor Suppressor Transcription FactorsJing Liu, Xufen Yu, He Chen, et al.Human Gene Therapy|August 25, 2023
Chemical Epigenetic Regulation of Adeno-Associated Virus Delivered TransgenesJessica D Umaña, Sara R Wasserman, Liujiang Song, et al.Bioorganic & Medicinal Chemistry Letters|November 21, 2017
Structure-activity relationships and docking studies of synthetic 2-arylindole derivatives determined with aromatase and quinone reductase 1Allan M Prior, Xufen Yu, Eun-Jung Park, et al.Science Advances|April 23, 2025
Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcomaYao Yu, Xufen Yu, Bo Pan, et al.Nucleic Acids Research|October 27, 2022
A cryptic transactivation domain of EZH2 binds AR and AR's splice variant, promoting oncogene activation and tumorous transformationJun Wang, Kwang-Su Park, Xufen Yu, et al.European Journal of Medicinal Chemistry|April 29, 2023
Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategySong Chen, Zhendong Chen, Lixue Lu, et al.Journal of Medicinal Chemistry|July 13, 2019
Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68)Xufen Yu, Xi-Ping Huang, Terry P Kenakin, et al.Journal of Medicinal Chemistry|June 25, 2015
Structure-based design of potent HIV-1 protease inhibitors with modified P1-biphenyl ligands: synthesis, biological evaluation, and enzyme-inhibitor X-ray structural studiesArun K Ghosh, Xufen Yu, Heather L Osswald, et al.Journal of Medicinal Chemistry|October 5, 2022
Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant CellsXufen Yu, Jia Xu, Kaitlyn M Cahuzac, et al.Pageof 6